Pfizer presents LITFULO data. 10 analysts rate Pfizer stock Buy

Published on 10/05/2026 at 10:17 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Pfizer's LITFULO reached 21.86 percent at Week 52 on October 2, 2026. Pfizer stock costs EUR 24.86 versus EUR 24.70.

Editorialfoto eines Trading-Floors mit Sektor-Charts, Symbolbild für den Aktienhandel von Pfizer Inc — Börsen-Editorialfoto vom Trading-Floor mit Pharma-Charts steht sinnbildlich für den Aktienhandel von Pfizer Inc., ISIN US7170811035, Illustration mit AI erstellt.

Pfizer Inc. (ISIN US7170811035) presented Phase 3 LITFULO data on October 2, 2026, with 21.86 percent of patients on the 100 mg dose achieving at least 75 percent facial repigmentation at Week 52 versus 2.40 percent on placebo, according to Morningstar. Investing.com lists 10 analyst buy recommendations and two sell recommendations for Pfizer stock.

LITFULO expands the pipeline

The TRANQUILLO 2 and TRANQUILLO studies evaluated 2,174 patients across 271 sites. In the lower-dose study, 12.47 percent of patients achieved the facial endpoint versus 2.48 percent on placebo, while total-body repigmentation of at least 50 percent reached 13.02 percent with the 100 mg dose versus 2.40 percent for placebo, according to Morningstar.

Pfizer said the results support planned submissions to the U.S. Food and Drug Administration and the European Medicines Agency. The commercial significance depends on regulatory review, but the data give Pfizer a potential second indication for LITFULO, which is already approved for severe alopecia areata.

Second-quarter revenue reached USD 15.03 billion

Pfizer reported USD 15.03 billion in revenue for the second quarter of 2026 and adjusted earnings per share of USD 0.77, above the USD 0.68 consensus estimate, according to Investing.com. The revenue figure exceeded the cited forecast of USD 14.42 billion, creating a quantified comparison alongside the newer pipeline data.

The same second-quarter update described full-year 2026 revenue guidance of USD 60.5 billion to USD 62.5 billion after a USD 500 million increase to the range. Adjusted earnings per share guidance remained USD 2.80 to USD 3.00, while the COVID revenue outlook was reduced to USD 4.00 billion from USD 5.00 billion, according to Investing.com.

Stock price and next reporting date

On the NYSE, Pfizer was last quoted at USD 27.80 on October 2, 2026 at 4:01 p.m. ET, against a 52-week range of USD 23.62 to USD 29.21. Its market capitalization was USD 158.4 billion on that date. The next quarterly report is scheduled for November 3, 2026, according to StockTitan.

Pfizer stock was trading at EUR 24.86 at Lang & Schwarz on October 5, 2026 at 10:08 a.m. CEST, up 0.65 percent versus the prior close of EUR 24.70. The further course of trading is shown by the continuously updated real-time quote of Pfizer stock.